Who We Are
Leo Groenewegen, Business Developer BBA, Health Economist, responsible for business development.
Edvard Smith, Medical director MD, professor, co-founder and medically responsible for NextCell Pharma AB and Cellaviva.
Sofie Falk Jansson, Marketing & Sales director, experienced marketeer within business to consumer.
Maria Hägg, QA/RA manager Ph.D. Background from clinical grade cell production and advanced therapeutic medicinal products (ATMP).
Who We Are
Hans-Peter Ekre Background as investment manager at Karolinska Development and R&D manager at Pharmacia, Astra and Biotech companies.
Pingis Hadenius Economist and entrepreneur. Co-founder of i.a. Löwengrip AB, Nordic Tech House AB and Flattered AB.
Who We Are
The board of directors deems the market for stem cell treatment of autoimmune diabetes to be extensive. At present there are some 20-40 million people with autoimmune Type 1 diabetes, and around 80,000 are diagnosed every year, many of them children. There is also an equally common, though slower, advancing form of autoimmune diabetes among adults, known as Latent Autoimmune Diabetes in the Adult (LADA). Autoimmune diabetes is increasingly being diagnosed using blood tests, where the occurrence of at least two antibodies against the insulin-producing beta cells indicates the existence of the autoimmune illness. In autoimmune diabetes, the insulin-producing beta cells are attacked by the body’s immune system until the patient can no longer produce enough of its own insulin to keep the blood sugar concentration within normal limits. NextCell’s aim is to treat the diabetic with ProTrans™ in the form of transplanted stem cells, which suppresses the body’s autoimmune reaction to the beta cells, thereby potentially leading to a normal level of blood sugar concentration. The board estimates that the market potential for a drug like ProTrans™ for treating autoimmune diabetes is several billion dollars a year. NextCell today is unaware of any drug that cures the patient of the disease.
Every year some 50,000 kidney transplants are carried out using kidneys from deceased donors. Various complications can arise when transplanting a kidney, one being that the recipient’s body will not accept the new kidney and instead tries to reject it. The risk of rejection is far higher if the kidney is taken from a deceased donor than from a living donor. The board believes that the company’s product, ProTrans™, could potentially be used to protect the transplanted organ and create the conditions for the recipient’s immune system to accept the new kidney. The company therefore believes that the need for immunosuppressive drugs would decrease. Immunosuppressive drugs are used so that the body’s immune system reacts pathologically, i.e. in a non-normal way. Immunosuppressants are used, for instance, in many autoimmune diseases and place a serious burden on the patient’s health. They make the body susceptible to viruses, bacteria and parasitic infections, and the board therefore deems there to be an extensive market potential for ProTrans™ in kidney transplantation. The board estimates this market potential at several billion dollars globally.
Cellaviva is Sweden’s first stem cell bank. Cellaviva has been on the market since September 2015, but has not yet made a market breakthrough.
NextCell and its activities are supported by EIT (Health), an EU body